Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.45 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.45 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.45 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.45 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.45 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.45 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.45 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.45 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.45 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.45 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.45 |
| ▸ | PSMB3 | P49720 | 1/20 | 0.45 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.45 |
| ▸ | PSMA6 | P60900 | 1/20 | 0.45 |
| ▸ | PSMA8 | Q8TAA3 | 1/20 | 0.45 |
| ▸ | PSMB7 | Q99436 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16658739 | 0.92 | PSMB11 (0.54) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL16658738 | 0.92 | PSMB11 (0.54) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL16658735 | 0.92 | PSMB11 (0.54) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL16658734 | 0.92 | PSMB11 (0.54) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL16658737 | 0.92 | PSMB11 (0.54) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL16658745 | 0.92 | PSMB11 (0.54) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL10016300 | 0.92 | PSMB11 (0.54) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL16658736 | 0.92 | PSMB11 (0.54) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL12048773 | 0.90 | PSMB11 (0.53) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL22294215 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4599890-A2 | SUNITINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2025-08-13 | — | — | EP | disclosed |
| US-20240358641-A1 | PROCESSES FOR MAKING CYCLIC LIPID IMPLANTS FOR INTRAOCULAR USE | ALLERGAN, INC. | 2024-10-31 | — | — | US | disclosed |
| US-20240207287-A1 | POLYMERIC IMPLANTS | ALLERGAN INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240173236-A1 | Topical Testosterone (T) for Promoting Hair Growth-Containing Formulations | CORBOY JR EDWARD DUNNE (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240082262-A1 | TOPICAL COMPOSITIONS COMPRISING BIMATOPROST AND METHODS FOR STIMULATING HAIR GROWTH THEREWITH | ALLERGAN, INC. | 2024-03-14 | — | — | US | disclosed |
| US-11833238-B2 | Topical testosterone (T) for promoting hair growth-containing formulations | CORBOY JR EDWARD DUNNE (US) | 2023-12-05 | — | — | US | disclosed |
| CN-113181362-B | Medicament for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2023-06-13 | — | — | CN | disclosed |
| US-20220226346-A1 | TOPICAL COMPOSITIONS COMPRISING BIMATOPROST AND METHODS FOR STIMULATING HAIR GROWTH THEREWITH | ALLERGAN, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220087918-A1 | Topical Testosterone (T) for Promoting Hair Growth-Containing Formulations | CORBOY JR EDWARD DUNNE (US) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226346-A1 | TOPICAL COMPOSITIONS COMPRISING BIMATOPROST AND METHODS FOR STIMULATING HAIR GROWTH THEREWITH | FGF1, CYP21A2, HDGF | PSMB11 3034/4885PSMA7 2458/4885PSMB1 2864/4885 |
| US-20240207287-A1 | POLYMERIC IMPLANTS | PDE6C, PDE6A, PHOSPHO1 | PSMB11 3027/4885PSMA7 2969/4885PSMB1 3705/4885 |
| US-20240082262-A1 | TOPICAL COMPOSITIONS COMPRISING BIMATOPROST AND METHODS FOR STIMULATING HAIR GROWTH THEREWITH | FGF1, CYP21A2, HDGF | PSMB11 3034/4885PSMA7 2458/4885PSMB1 2864/4885 |
| US-20240358641-A1 | PROCESSES FOR MAKING CYCLIC LIPID IMPLANTS FOR INTRAOCULAR USE | LIPA, PDE6C, PDE6A | PSMB11 4058/4885PSMA7 3923/4885PSMB1 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.